Acute myocardial infarction mortality in Chile. Thrombolysis or angioplasty Mortalidad por infarto del miocardio en Chile. Trombolíticos o angioplastía
Author
dc.contributor.author
Fernando Florenzano,
Admission date
dc.date.accessioned
2019-03-11T13:03:07Z
Available date
dc.date.available
2019-03-11T13:03:07Z
Publication date
dc.date.issued
2011
Cita de ítem
dc.identifier.citation
Revista Medica de Chile, Volumen 139, Issue 11, 2018, Pages 1393-1395
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.issn
07176163
Identifier
dc.identifier.other
10.4067/S0034-98872011001100001
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165471
Abstract
dc.description.abstract
During recent decades, acute myocardial infarction short-term mortality has decreased to one digit levels, in the United States. Data from Chilean registries give figures around 11% for patients receiving thrombolysis, and 5 to 6 % for patients treated with angioplasty. The decrease in mortality in Chile is related to the implementation of the AUGE program at a national level, initiative than gives patients the opportunity to receive at least thrombolytic therapy as well as a standardized and rapid diagnosis and treatment for this condition. There is a lack of Outcome Research studies in Chile, that would guide public health decisions such as the use of fibrin-specific agents for early presentation and high risk cases, and a rational system providing better access to primary angioplasty.
Acute myocardial infarction mortality in Chile. Thrombolysis or angioplasty Mortalidad por infarto del miocardio en Chile. Trombolíticos o angioplastía